Immutrin Ltd has raised £65 million to advance its lead antibody therapy to treat ATTR cardiomyopathy, a serious form of amyloidosis. The oversubscribed Series A financing was led by new investor Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and the biotech company’s founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures, UK. Amyloidosis is caused by misfolded proteins that aggregate into amyloid fibrils and accumulate in tissues and organs, leading to irreversible organ damage.
